CD73: A potential biomarker for anti-PD-1 therapy
Oncoimmunology, 2015•Taylor & Francis
In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1
therapy, and this is rescued by concomitant A2A blockade. Since CD73 is known to be
overexpressed in several human cancers and A2A antagonists have undergone clinical
trials for Parkinson's Disease, this combination warrants further investigation.
therapy, and this is rescued by concomitant A2A blockade. Since CD73 is known to be
overexpressed in several human cancers and A2A antagonists have undergone clinical
trials for Parkinson's Disease, this combination warrants further investigation.
In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A2A blockade. Since CD73 is known to be overexpressed in several human cancers and A2A antagonists have undergone clinical trials for Parkinson's Disease, this combination warrants further investigation.
Taylor & Francis Online